Intramuscular Neostigmine for Accelerating Bladder Emptying after Cesarean Section by Spinal Anesthesia

Evidence Based Women's Health Journal Pub Date : 2023-11-01 DOI:10.21608/ebwhj.2023.217484.1256

Aml Aljaml, Mohamed Elnegery, Nermeen Shams-Eldien, Khalid Samir, Mohamed Abdelhafez

{"title":"Intramuscular Neostigmine for Accelerating Bladder Emptying after Cesarean Section by Spinal Anesthesia","authors":"Aml Aljaml, Mohamed Elnegery, Nermeen Shams-Eldien, Khalid Samir, Mohamed Abdelhafez","doi":"10.21608/ebwhj.2023.217484.1256","DOIUrl":null,"url":null,"abstract":"Objective: To assess the efficacy of intramuscular (IM) neostigmine administration for acceleration of urinary bladder (UB) emptying and prevention of postoperative urine retention (POUR) following cesarean section (CS) performed under spinal anesthesia. Patients and Methods: Randomized controlled trial conducted on pregnant women who were planned to undergo elective CS under spinal anesthesia. All participants were randomly allocated after surgery into 2 groups; neostigmine group who received 0.5 mg IM neostigmine, and placebo group who received IM NaCl 0.9%. The primary outcome measures were time to first voiding after treatment and time to first voiding after catheter removal, and the secondary outcome measures were volume of excreted urine, postvoid residual bladder volume (PVRBV) and catheterization rate. Results: A total of 100 women (50 women in each group) were subjected to final analysis. Time to first voiding after treatment was significantly lower in neostigmine group than in placebo group (266.94 ± 77.53 vs 303.72 ± 64.07 min; P = 0.027). Also, time to first voiding after catheter removal was significantly lower in neostigmine group than in placebo group (214.90 ± 66.53 vs 241.60 ± 61.73 min; P = 0.036). However, there were no significant difference between both groups in volume of excreted urine, PVRBV and catheterization rate. Conclusion:","PeriodicalId":12080,"journal":{"name":"Evidence Based Women's Health Journal","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Women's Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ebwhj.2023.217484.1256","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess the efficacy of intramuscular (IM) neostigmine administration for acceleration of urinary bladder (UB) emptying and prevention of postoperative urine retention (POUR) following cesarean section (CS) performed under spinal anesthesia. Patients and Methods: Randomized controlled trial conducted on pregnant women who were planned to undergo elective CS under spinal anesthesia. All participants were randomly allocated after surgery into 2 groups; neostigmine group who received 0.5 mg IM neostigmine, and placebo group who received IM NaCl 0.9%. The primary outcome measures were time to first voiding after treatment and time to first voiding after catheter removal, and the secondary outcome measures were volume of excreted urine, postvoid residual bladder volume (PVRBV) and catheterization rate. Results: A total of 100 women (50 women in each group) were subjected to final analysis. Time to first voiding after treatment was significantly lower in neostigmine group than in placebo group (266.94 ± 77.53 vs 303.72 ± 64.07 min; P = 0.027). Also, time to first voiding after catheter removal was significantly lower in neostigmine group than in placebo group (214.90 ± 66.53 vs 241.60 ± 61.73 min; P = 0.036). However, there were no significant difference between both groups in volume of excreted urine, PVRBV and catheterization rate. Conclusion:

查看原文本刊更多论文

肌肉注射新斯的明加速脊髓麻醉下剖腹产术后的膀胱排空

目的评估在脊髓麻醉下进行剖宫产术（CS）后，肌肉注射（IM）新斯的明对加速膀胱（UB）排空和预防术后尿潴留（POUR）的疗效。患者和方法：随机对照试验针对计划在脊柱麻醉下接受择期剖腹产手术的孕妇。所有参与者在手术后被随机分为两组：新斯的明组接受 0.5 毫克 IM 新斯的明，安慰剂组接受 0.9% NaCl IM。主要结果指标为治疗后首次排尿时间和拔除导尿管后首次排尿时间，次要结果指标为排出尿量、排尿后残余膀胱容量（PVRBV）和导尿率。结果共有 100 名妇女（每组 50 人）接受了最终分析。新斯的明组治疗后首次排尿的时间明显低于安慰剂组（266.94 ± 77.53 vs 303.72 ± 64.07 min; P = 0.027）。此外，新斯的明组拔除导管后首次排尿的时间也明显低于安慰剂组（214.90 ± 66.53 vs 241.60 ± 61.73 分钟；P = 0.036）。然而，两组在排尿量、PVRBV 和导尿率方面没有明显差异。结论

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Evidence Based Women's Health Journal

自引率

0.00%

发文量